PepLabo Download

Victoza® and stomach pain

Stomach pain on Victoza®: upper-belly pain in EU and Canadian data, the pancreas and gallbladder warnings, other causes and when to get help.

Published · Updated · Victoza®: side effects by symptom · Written by the PepLabo editorial team

When to get help
Context and scope

Stomach pain is one of the more confusing symptoms on Victoza®. Most of the time it travels with the familiar digestive effects of starting a daily liraglutide injection, yet the same label names two organ problems, pancreatitis and gallbladder disease, whose first sign is pain. This page sets out what the US, European and Canadian product information record, what the long LEADER trial added, and how to tell a nuisance from a warning.

Key takeaways 5
  • The US label’s Table 1 lists dyspepsia at 4% on 1.2 mg and 7% on 1.8 mg versus 1% on placebo; abdominal pain does not reach its 5% cut-off. [1]
  • EU product information rates upper abdominal pain, abdominal discomfort and gastritis as common and says digestive reactions usually fade within days or weeks. [2]
  • In the LEAD-2 trial, upper abdominal pain was recorded in 2.1% to 3.3% of people on Victoza® with metformin and in none on placebo. [3]
  • In LEADER, acute gallbladder or bile duct events were more frequent with liraglutide (141 vs 88 people), while confirmed acute pancreatitis was not (0.4% vs 0.5%). [5][6]
  • Severe stomach pain that will not go away, with or without vomiting, is the Medication Guide’s signal to stop Victoza® and call your prescriber. [1]

Where stomach pain appears in the product information

The three main sources count side effects in different ways, which explains why stomach pain seems to be missing from one and present in the others. The US label pools five placebo-controlled glycemic trials in 1,673 adults treated with Victoza® for an average of 37.3 weeks, and its Table 1 only shows reactions that reached 5% and were more frequent than on placebo. [1] Indigestion made it; abdominal pain did not. The European summary of product characteristics sorts reactions into frequency classes, and places upper abdominal pain, abdominal discomfort, gastritis and a swollen abdomen in the common class. [2] The Canadian monograph prints each trial separately and lists every event seen in at least 1% of people, whether or not an investigator thought the drug caused it. [3]

Stomach pain and related rows for Victoza® in official product information (checked 20-10-2026)
Source and termVictoza® 0.6 mg1.2 mg1.8 mgComparison group
US label, Table 1: dyspepsia (five placebo-controlled trials) [1]—4%7%Placebo 1%
Canada, LEAD-2 (with metformin, 26 weeks): upper abdominal pain [3]2.1%2.9%3.3%Placebo 0.0%; glimepiride 1.2%
Canada, LEAD-2: abdominal pain [3]0.8%1.7%2.5%Placebo 1.7%; glimepiride 0.4%
Canada, LEAD-5 (with metformin and glimepiride): upper abdominal pain [3]——4.3%Placebo 1.8%; insulin glargine 0.9%
Canada, trial 1860 (with metformin): upper abdominal pain [3]—2.3%1.8%Sitagliptin 0.9%
EU SmPC, Table 1 [2]Common (1 in 100 to 1 in 10): upper abdominal pain, abdominal discomfort, gastritis, abdominal distension, reflux

Timing: the first months and each dose step

The European information says digestive reactions are more frequent at the start of treatment and usually settle within a few days or weeks. [2] The US label points the same way from another angle: in its pooled trials, 4.3% of people on Victoza® stopped because of digestive reactions, against 0.5% on placebo, and those withdrawals happened mostly in the first two to three months. [1] Severe digestive reactions were reported by 4.4% on 1.2 mg and 4.2% on 1.8 mg, compared with 1.1% on placebo. [1]

The label starts adults at 0.6 mg a day for a week before moving to 1.2 mg, with a possible later step to 1.8 mg. [1] If more than three days pass without a dose, it says to restart at 0.6 mg to reduce the digestive reactions that can come with restarting. [1] Liraglutide has a half-life of about 13 hours and reaches its highest level 8 to 12 hours after an injection, which is why it is given every day. [1] So unlike a once-weekly medicine, there is no weekly injection day to line symptoms up against; the useful comparisons are the time of the daily dose, meals and the weeks after a dose step.

When pain is the warning: pancreas and gallbladder

Section 5.2 of the US label asks prescribers to watch for acute pancreatitis after Victoza® is started. Its typical sign is persistent or severe abdominal pain, sometimes running through to the back, which may or may not come with nausea or vomiting. [1] In the glycemic control trials there were 13 cases among people on Victoza® and one on a comparator. [1] The much larger LEADER trial adjudicated every suspected case: confirmed acute pancreatitis occurred in 18 people on liraglutide (0.4%) and 23 on placebo (0.5%), most more than a year after randomisation. [5] Lipase and amylase rose on liraglutide, by 28% and 7% relative to placebo, but those rises did not predict who would develop pancreatitis. [5]

The gallbladder story runs the other way. In LEADER, 3.1% on Victoza® and 1.9% on placebo had an acute gallbladder event such as gallstones or inflammation, and most needed hospital care or gallbladder removal. [1] A later analysis of the same trial counted 141 of 4,668 people on liraglutide against 88 of 4,672 on placebo (hazard ratio 1.60), with a similar pattern for stones, inflammation and bile duct blockage; the authors note that the trial was not designed for this question and that the mechanism needs further study. [6] Canada’s patient information describes an inflamed gallbladder as upper abdominal pain after eating, especially a fatty meal, with nausea, bloating and indigestion. [3] Rarely, a blocked bowel can also begin as stomach ache with bloating and vomiting; the EU leaflet calls it a severe form of constipation. [2]

Why it happens: what is shown and what is not

What the label supports: part of how liraglutide lowers blood sugar after meals is by slowing how fast the stomach empties. [1] Food staying longer in the stomach fits with indigestion, fullness and upper-belly discomfort, and the European table also lists delayed gastric emptying as an uncommon reaction in its own right. [2] Constipation, another Victoza® row (5% on either dose against 1% on placebo), can cause cramping pain of its own. [1][7]

What is not settled: why gallbladder events rose in LEADER. The authors of the LEADER gallbladder analysis say the mechanism should be studied further, so any single explanation offered online is a hypothesis. [6] For pancreatitis the trial picture is mixed: the glycemic control trials counted more cases on Victoza® (13 against 1), while the larger LEADER trial, which had every case checked by a blinded committee, did not (18 against 23). [1][5]

Other reasons your stomach can hurt

MedlinePlus groups belly pain by its pattern. Pain across more than half of the abdomen is more typical of a stomach virus, indigestion or gas; pain in one spot points more toward an organ such as the appendix, gallbladder or stomach; cramping is usually gas or bloating; and pain that comes in waves is often caused by kidney stones or gallstones. [7] It also stresses that the strength of the pain does not always match how serious the cause is. [7]

Common, less serious causes include constipation, irritable bowel syndrome, food intolerance, food poisoning and stomach flu. Others need a clinician: ulcers, reflux, diverticulitis, urinary tract infection, kidney stones, appendicitis and bowel blockage among them. [7] For someone with type 2 diabetes, a new pain is worth describing rather than assuming it belongs to the medicine.

What the leaflets and MedlinePlus describe

The Victoza® Medication Guide asks you to drink fluids so that nausea, vomiting or diarrhea do not leave you dehydrated, and to tell your healthcare provider about stomach problems that are severe or do not go away. [1] The European leaflet gives the same fluid advice for the start of treatment. [2]

For mild belly pain, MedlinePlus describes sipping water or other clear fluids, skipping solid food for a few hours and returning to small amounts of mild food. It reminds people with diabetes to check their blood sugar often while they are unwell. If pain sits high in the abdomen after meals with heartburn, it notes that an antacid may help, and that citrus, fatty or fried food, tomato products, caffeine, alcohol and fizzy drinks are worth avoiding. It also says not to take any medicine for the pain without talking to your provider; a pharmacist can help with that question. [7] Smaller, more frequent meals, enough water, fibre and regular activity are listed as ways to prevent some kinds of belly pain. [7]

Victoza® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk A/S.

When to get help

The signs and contact information below come from this article’s sourced guidance.

Emergency

  • Severe stomach pain that will not go away, with or without vomiting, possibly felt through to the back

    Contact: Stop Victoza® and call your prescriber right away

    Medication Guide [1]

  • Sudden sharp belly pain, a hard or rigid belly, vomiting blood, black or bloody stools, or being unable to pass stool while vomiting

    Contact: Emergency services (911 or local number)

    MedlinePlus [7]

Today

  • Upper stomach pain with fever, yellow skin or eyes, or clay-coloured stools

    Contact: Your prescriber, the same day

    Medication Guide [1]

  • Pain with vomiting or diarrhea that does not stop, or being unable to keep fluids down

    Contact: Your prescriber, the same day (dehydration and kidney risk)

    Medication Guide [1]; MedlinePlus [7]

At your next appointment

  • Pain that has not improved in 24 to 48 hours, or discomfort lasting a week or more

    Contact: Contact your health care provider

    MedlinePlus [7]

  • Mild upper-belly discomfort or indigestion in the first weeks or after a dose step

    Contact: Mention it at your next appointment

    EU SmPC [2]; Medication Guide [1]

Questions

Is upper-belly pain on Victoza® common?

The European product information classes upper abdominal pain as common, between 1 and 10 in 100 people. [2] In the Canadian trial tables it ranged from about 2% to 4% on Victoza®, against 0% to 1.8% on placebo. [3]

Does the 1.8 mg dose cause more stomach pain than 1.2 mg?

For indigestion, the US figures are 4% on 1.2 mg and 7% on 1.8 mg. [1] For upper abdominal pain the Canadian trials do not show a steady rise: 2.9% and 3.3% in LEAD-2, 2.3% and 1.8% in trial 1860. [3]

My lipase was high on a blood test but I have no pain. Is that pancreatitis?

In LEADER, lipase and amylase rose with liraglutide but did not predict later pancreatitis. [5] The US label says the meaning of raised enzymes without other signs of pancreatitis is unknown, so this is a question for your prescriber. [1]

I had gallstones before. Does that matter on Victoza®?

The label warns about acute gallbladder disease and asks for gallbladder studies if stones are suspected. [1] LEADER found more gallbladder and bile duct events with liraglutide than placebo. [6] Make sure your prescriber knows your history.

My teenager uses Victoza®. Is stomach pain handled differently?

The US label says the type and severity of side effects in patients aged 10 and older were comparable to adults. [1] In the paediatric trial, overall rates of digestive side effects were higher with liraglutide than placebo. [4] The same warning signs apply.

I switched to generic liraglutide. Should the stomach effects change?

The FDA approval of the first generic referencing Victoza® lists the same most common side effects and warnings, including pancreatitis and gallbladder disease. [8] If something changes after a switch, note it and tell your prescriber or pharmacist.

Sources

Sources checked on

  1. VICTOZA® (liraglutide) injection Prescribing Information and Medication Guide, Novo Nordisk Revised 10/2025; Medication Guide 05/2025. Sections 2.1, 2.2, 5.2, 5.6, 5.8, 6.1, 6.2, 8.4 and 12.1–12.3.
  2. Victoza: EPAR – Product Information (SmPC and package leaflet), European Medicines Agency SmPC sections 4.4 and 4.8 (Table 1, read from the PDF page image); package leaflet section 4.
  3. VICTOZA® (liraglutide injection) Product Monograph, Novo Nordisk Canada Inc. (Health Canada Drug Product Database) Date of authorization 2025-08-21. Section 8.2 (Tables 1 and 2, read from the PDF page images); patient medication information.
  4. Tamborlane WV et al. Liraglutide in children and adolescents with type 2 diabetes (Ellipse). N Engl J Med 2019 Randomised controlled trial; PubMed abstract.
  5. Steinberg WM et al. Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized trial. Diabetes Care 2017 Analysis of a randomised trial; PubMed abstract.
  6. Nauck MA et al. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial. Diabetes Care 2019 Post hoc analysis of a randomised trial; PubMed abstract.
  7. Abdominal pain, MedlinePlus Medical Encyclopedia (U.S. National Library of Medicine)
  8. FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes, U.S. FDA December 23, 2024.